Business Context and Reporting Period
Company: PainReform Ltd. (PRF Technologies Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2023 (Specifically December 26, 2023)
Context: The Company entered into an inducement offer letter agreement with a holder of existing warrants to facilitate the exercise of those warrants at a reduced price in exchange for the issuance of new warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise transaction rather than standard operating financial results. Key metrics include:
- Expected Gross Proceeds: Approximately $1.3 million from the exercise of existing warrants.
- Shares to be Issued (Existing Warrants): 467,896 ordinary shares.
- Reduced Exercise Price: $2.85 per share (reduced from the original $9.00).
- New Warrants Issued: 935,792 new warrants to purchase ordinary shares at $2.85 per share.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Non-accountable expenses: $25,000.
- Clearing fees: $15,950.
- Tail financing fee: 6.5% of gross proceeds (related to July 2023 offerings).
- Placement Agent Warrants: 32,753 shares at an exercise price of $3.5625.
Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the restructuring of warrant terms to induce cash exercise:
- Price Reduction: The exercise price for 467,896 existing warrants was reduced from $9.00 to $2.85 per share.
- Dilution: The transaction results in the issuance of 467,896 shares upon exercise and 935,792 new warrants, significantly increasing potential share count.
- Use of Proceeds: Net proceeds are designated for research and development, clinical trials, working capital, and general corporate purposes.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- The closing of the transaction is expected on or about December 29, 2023, subject to customary conditions.
- The Company intends to file a resale registration statement (Form F-3) for the new warrant shares within 90 days of the inducement letter date.
Risks and Contingencies:
- Closing Conditions: The transaction is not guaranteed and is subject to satisfaction of customary closing conditions.
- Liquidity: There is no established trading market for the new warrants, and liquidity is expected to be extremely limited.
- Forward-Looking Statements: The Company warns that forward-looking statements regarding the closing date and future performance are not guaranteed.
- Lock-up Restrictions: The Company agreed not to issue ordinary shares or equivalents for 15 days post-closing and not to effect Variable Rate Transactions for one year post-closing.
Investor Verification Checklist
- Verify the actual closing date of the transaction (expected Dec 29, 2023) and confirmation of fund receipt.
- Confirm the effective date of the resale registration statement for the new warrant shares.
- Review the impact of the 467,896 new shares and 935,792 new warrants on fully diluted share count and per-share value.
- Assess the total cost of capital including the 7.0% cash fee, 1.0% management fee, 6.5% tail fee, and the issuance of placement agent warrants.
- Monitor the Company's cash burn rate relative to the $1.3 million gross proceeds to determine runway for clinical trials.